Caxton Associates LP Prelude Therapeutics Inc Transaction History

Caxton Associates LP

  • $2.65 Billion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023
SELL
$4.61 - $8.5 $94,684 - $174,581
-20,539 Reduced 23.88%
65,453 $395,000
Q3 2022

Nov 14, 2022
BUY
$5.0 - $8.82 $10,625 - $18,742
2,125 Added 2.53%
85,992 $568,000
Q2 2022

Aug 15, 2022
BUY
$4.0 - $7.55 $335,468 - $633,195
83,867 New
83,867 $438,000

Others Institutions Holding PRLD

# of Institutions
71
Shares Held
35.7M
Call Options Held
500
Put Options Held
300
View Full List

About Prelude Therapeutics Inc

PRLD Quotes by TradingView
  • Ticker PRLD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,369,200
  • Market Cap $34.6M
  • Description
  • Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid ...
More about PRLD
Track This Portfolio

Track Caxton Associates LP Portfolio

Follow Caxton Associates LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Caxton Associates LP, based on Form 13F filings with the SEC.

News

Stay updated on Caxton Associates LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email